Welcome to our dedicated page for Vita Coco Company SEC filings (Ticker: COCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vita Coco Company, Inc.'s SEC filings document financial results, operating updates, governance matters, and public-company disclosures for its beverage brand portfolio. Form 8-K reports include quarterly and annual results, guidance updates, Regulation FD disclosures, and other material events related to the company’s coconut water and better-for-you beverage operations.
Proxy materials describe annual meeting proposals, board structure, committee assignments, executive compensation, equity awards, and stockholder voting matters. Additional 8-K filings record director appointments, board retirements, officer roles, compensation arrangements, tariff-related disclosures, and the company’s capital-market reporting obligations as a Nasdaq-listed Delaware corporation.
Ira Liran, a director of Vita Coco Company, Inc. (COCO), reported the sale of 3,152 shares of company common stock on 08/22/2025 under a Rule 10b5-1 trading plan at a weighted average price of $37.022 per share. Following the transaction, Mr. Liran directly beneficially owns 635,189 shares and indirectly beneficially owns 782,579 shares through the Ira Liran 2012 Family Trust. The filing was submitted by an attorney-in-fact on behalf of the reporting person on 08/25/2025 and includes an undertaking to provide detailed per-price sale information on request.
Kenneth Sadowsky, a director of The Vita Coco Company, Inc. (COCO), sold 3,900 shares of common stock under a Rule 10b5-1 trading plan on 08/20/2025 at a weighted average price of $35.448, with transaction prices ranging from $34.91 to $35.78. After the sale he beneficially owned 627,766 shares directly. The filing also reports a fully vested non-qualified stock option with a $10.178 exercise price covering 27,300 shares, exercisable through 01/02/2030. The Form 4 was signed by Alison Klein as attorney-in-fact on 08/22/2025. The filing indicates the sale was effected pursuant to a pre-established trading plan and discloses the weighted average and price range for the multiple trades executed.
Ira Liran, a director of Vita Coco Company, Inc. (COCO), reported the sale of 30,000 shares of common stock on 08/20/2025 under a Rule 10b5-1 trading plan at a weighted average price of $36.08 per share. The filing states the shares were sold in multiple transactions at prices ranging from $36.00 to $36.30 and that the sold shares are held by the Ira Liran 2012 Family Trust.
After the reported transactions the filing discloses beneficial holdings of 782,579 shares indirectly by the Ira Liran 2012 Family Trust and 638,341 shares directly. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Liran and indicates the sale was made pursuant to an established trading plan.
The filing is a Form 144 notice regarding proposed sale of common stock of The Vita Coco Company, Inc. (COCO). It discloses a proposed sale of 140,000 shares of common stock through The Charles Schwab Corporation on NASDAQ with an approximate aggregate market value of $6,040,000 and an approximate sale date of 08/22/2025. The filing reports 56,822,981 shares outstanding.
The shares to be sold were acquired as stock compensation on 08/11/2009 (140,000 shares). The form also records a recent sale by the same account: 30,000 shares sold on 08/20/2025 for gross proceeds of $1,082,391. Several form sections (filer identity and relationship to issuer) are not populated in the provided content.
Form 144 filing for The Vita Coco Company, Inc. (COCO) reports a proposed sale of 210,000 common shares through Charles Schwab, with an aggregate market value of $8,862,391.00. The filer acquired these shares on 08/11/2009 as stock compensation from the issuer. The filing lists 56,822,981 shares outstanding and an approximate sale date of 08/20/2025. The notice states no securities were sold by the account in the past three months and includes the filer’s representation about absence of undisclosed material adverse information.
Charles van Es, Chief Sales Officer of Vita Coco Company, Inc. (COCO), reported a mandated disposition of 9,799 shares on 08/15/2025 to satisfy tax withholding at a price of $33.07 per share. After that transaction he beneficially owned 84,328 shares. The filing also lists outstanding non-qualified stock options exercisable or vesting into common stock: 103,750, 27,300, 58,043, 42,980, 14,205, 8,746 and 13,218 shares under various grants and exercise prices, representing a total of 268,242 underlying shares. The reported disposition was a company-mandated share withholding tied to RSU settlement, not a discretionary sale by the reporting person.
Jonathan Burth, Chief Operating Officer of Vita Coco Company, Inc. (COCO), reported insider transactions on Form 4. On 08/15/2025 he disposed of 10,801 shares of Common Stock at $33.07 per share, leaving him with 86,127 shares beneficially owned. The filing states the disposition represented shares withheld to cover tax withholding for vested Restricted Stock Units and was mandated by the issuer, not a discretionary sale. The report also lists multiple non-qualified stock options held by Mr. Burth with varying strike prices ($10.178 to $33.36) and exercisable share amounts ranging from 8,746 to 222,950, some fully vested and currently exercisable and others subject to multi-year vesting schedules.
Jane Prior, Chief Marketing Officer of Vita Coco Company, Inc. (COCO), reported a mandated disposition of 10,522 shares of common stock on 08/15/2025 at a price of $33.07 per share to cover tax withholding related to the vesting and settlement of restricted stock units. After that transaction she beneficially owned 123,666 shares. The filing also discloses a portfolio of outstanding non-qualified stock options with exercise prices ranging from $10.178 to $33.36 and various vesting schedules, several of which are fully vested and exercisable. The form was signed by an attorney-in-fact on behalf of the reporting person.
Issuer: The Vita Coco Company, Inc. (COMMON STOCK) CUSIP: 92846Q107.
Filing: Schedule 13G reporting event date 06/30/2025 and signature date 08/05/2025. Reporting persons are FMR LLC (Type: HC) and Abigail P. Johnson (Type: IN). Aggregate beneficial ownership reported is 3,324,879.26 shares, representing 5.9% of the class.
Cover-page specifics: FMR LLC reports sole voting power 3,323,769.00 and sole dispositive power 3,324,879.26; Abigail P. Johnson reports sole voting power 0.00 and sole dispositive power 3,324,879.26. Item 6 states other persons are known to have rights to dividends or proceeds but no other person holds >5%. Exhibit 99 and a Power of Attorney (referenced to prior filings) are noted.
Q2 FY25 highlights (ended 6/30/25):
- Net sales rose 17% YoY to $168.8 m; Americas +14%, International +37%.
- Gross profit increased 4% to $61.3 m, but margin compressed to 36.3% (-440 bp) as coconut input and logistics costs outpaced pricing.
- SG&A up 26% to $36.1 m (marketing and stock-based comp), driving a 16% drop in operating income to $25.1 m.
- Derivative gains ($1.1 m vs -$6.0 m) and FX gains lifted net income 20% to $22.9 m; diluted EPS $0.38 vs $0.32.
- Six-month net sales +17% to $299.7 m; net income +26% to $41.8 m; diluted EPS $0.70.
- Balance sheet robust: cash & equivalents $167 m, no revolver borrowings, net cash position. Equity climbed to $297 m. Purchase of 284,728 shares in Q2 ($8.6 m); $42.1 m authorization remains.
- Two customers represent 45% of YTD sales; private-label volumes expected to decline in H2.
- Tariff environment volatile: 10% baseline U.S. import tariff already impacting COGS; proposed 50% tariff on Brazilian sourcing could pressure margins further.
Liquidity: positive operating cash flow of $12 m YTD; undrawn $60 m credit facility extended to 2030.
Key watch-points for investors: ability to pass through cost inflation, tariff developments, customer concentration risk, and progress of international expansion.